Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacogenetic Strategies

This article was originally published in Start Up

Executive Summary

Stratifying patients in clinical trials based on their genes could help get new drugs approved faster, and revive failed compounds. Genomics companies have the infrastructure, technologies, and desire to make the science of pharmacogenetics their business. Start-ups are using people’s differing responses to drugs as platforms for new ‘personalized’ drug development strategies.

Related Content

Pharmacogenomics: Promises and Problems
Why Don't Big Pharmas Buy Pharmacogenomics?
Gentris Corp.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts